SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
January 14, 2026
INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD(TM) 2022
March 25, 2022
Related Post
-
-
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
January 9, 2026
-
NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway
January 8, 2026
-
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
January 6, 2026